Companies in #Cardiopulmonary Disease
Found 2 companies operating in this sector.
Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for serious diseases, with a lead program (GSBR-1290) in oral GLP-1 receptor agonism for obesity and type 2 diabetes. The company's pipeline targets GPCR-driven metabolic and cardiopulmonary diseases, leveraging structure-based drug design to create differentiated oral alternatives to injectable peptide therapies.
Tenax Therapeutics is a specialty pharmaceutical company developing therapies for pulmonary hypertension and other cardiovascular diseases with high unmet medical need. Lead candidate TNX-103 (oral imatinib) is being developed for Pulmonary Hypertension associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), a large and underserved patient population. The company has historically advanced levosimendan (TNX-101) in cardiogenic shock and has presented TNX-103 data at the 2026 ESC Congress.